377 / 879
98
99
100
101
0
50
100
150
200
250
Moyenne par patient du %de points ayant un gamma <
1
Date
ORL P1 IUPESM
0,0
0,4
0,8
1,2
1,6
2,0
2,4
2,8
0
50
100
150
200
250
ORL P1 IUPESM
95
96
97
98
99
100
0
50
100
150
200
250
Moyenneparpatient du%depointsayantun gamma<1
Date
ORL P1 IUPESM
N
°
contrôle
M. Pillet
et al. Quality Engineering (1997)
Ppk = 1.48
Ppm = 2.45
41
100
99 98 97 96 95 94 93
LSL
Target
SL
95
arget
100
SL
*
ample Mean 99,289
ample N
250
tDev(Within) 0,660528
tDev(Overall) 0,966656
Process Data
Cp
*
CPL 2,16
CPU *
Cpk 2,16
Pp
*
PPL 1,48
PPU *
Ppk 1,48
Cpm 1,39
Overall Capability
Potential (Within) Capability
PPM < LSL 8000,00
PPM > USL
*
PPM Total
8000,00
bserved Performance
PPM < LSL 0,00
PPM > USL *
PPM Total
0,00
Exp. Within Performance
PPM < LSL 4,56
PPM > USL *
PPM Total
4,56
Exp. Overall Performance
Process Capability of Capa pat 1 à 50
Index particularities
Non normal distrib.
risk
0.27%
Physical limit at 100
%
Lower Spec. Lim. only
Pp
Ppk, Ppm:
LSL
Target = 100% = max
•
In daily practice at ICL
:
Moving-Range (%)
Individual value. (%)
EWMA (%)
-
Head-and-neck treatments -
5. IMRT QC results (portal dosimetry) monitored with SPC
S
TANDARDIZE
03/10/17